Beste Konservative Behandlung Therapeuten - TOP-15 Ärzte

Dr. Carlo Meloni ist Kardiologe am italienischen Krankenhaus San Rafael in Mailand. Er ist spezialisiert auf die kardiale Rehabilitation nach Herzoperationen und die Behandlung von Herzinsuffizienz, Herzrhythmusstörungen, Herzinfarkt, Bluthochdruck, koronare Herzkrankheit. Carlo Meloni führt jährlich über 1.000 Echokardiogramme durch.

Bildung

• 1986 - Abschluss an der Medizinischen Fakultät der Universität Mailand, Italien.
• 1990 - Spezialisierung in Kardiologie an der Universität Mailand, Italien.

Professionelle Aktivität

• 1991-2010 - Kardiologe in der Abteilung für Herzrehabilitation am Krankenhaus San Rafael in Mailand, Italien.
• Seit 2010 - Leiter der Abteilung für Herzrehabilitation am Krankenhaus San Rafael in Mailand, Italien.

Erfahrung

2019 - 2022

Universität für Gesundheitswissenschaften, Medizinische Fakultät, Stadtkrankenhaus Ankara, Kardiologische Klinik, Ankara

2017 - 2019

Universität für Gesundheitswissenschaften, Medizinische Fakultät, Türkei, Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

2012 - 2017

Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

2012 - 2017

TR Karabük Universität, Medizinische Fakultät, Abteilung für Kardiologie

2006 - 2006

Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

2001 - 2006

Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

1996 - 2001

Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

Ausbildung

2017 Karabük Universität, Medizinische Fakultät, Abteilung für Kardiologie

2006 Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik

2001 Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Ankara, Kardiologie

1996 Universität Ankara, Medizinische Fakultät

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Prof. Markus Dücks ist Spezialist für diagnostische Radiologie und minimal-invasive Therapie.

Auszeichnungen

• Goldmedaille des Honorarprofessors der Medizinischen Universität in Osaka (Japan).
• Ehrenmitglied der DeGIR (Deutsche Gesellschaft für Interventionelle Radiologie und Minimalinvasive Therapie).

Ausbildung und Berufserfahrung

• 1982-1988 - Studium der Humanmedizin an der Johannes-Gutenberg-Universität Mainz.
• 1988 - Approbation und Approbation.
• 1988-1989 - Sanitätsoffizier der Bundeswehr.
• 1990 - Promotion in Radiologie, Thema: „Untersuchung des Einflusses der Dilatationsrate auf deren Erfolg sowie Schädigung der Gefäßwände bei der Ballonexpansion“, an der Johannes-Gutenberg-Universität Mainz.
• 1990-1996 Assistenzarzt in der Abteilung für Radiologie der Ruprecht- und Karls-Universität.
• 1996 - Oberarzt in der Abteilung für Radiodiagnostik der Ruprecht-Karls-Universität Heidelberg.
• 1998 – Promotion in diagnostischer Radiologie, Thema: Direkter Vergleich bildgebender Verfahren des Magenkarzinoms: Die Bedeutung optimierter Untersuchungstechniken in der klinischen Praxis und die ersten experimentellen Erfahrungen mit der Magnetresonanztomographie.
• 2000 - Stellvertretender Leiter der Abteilung für Strahlendiagnostik, Institut für Radiodiagnostik der Universität Heidelberg. Ruprecht-Karl.
• 2000-2002 Leiter des Zentrums für Bildgebung an der Orthopädischen Klinik der Universität Heidelberg.
• 2002-2003 - Leiter der Abteilung für Strahlendiagnostik, Chirurgische Klinik, Abteilung für Radiologische Diagnostik an der Universität Heidelberg. Ruprecht-Karl.
• 2003 - Chefarzt des Zentralinstituts für Radiologie und Neuroradiologie am Klinikum Nordwest in Frankfurt am Main.
• 2006 Außerordentlicher Professor in der Klinik für Radiologie der Universität Heidelberg.

Wissenschaftliche Tätigkeit

Markus Duks ist einer der ersten Ärzte, der die minimal-invasive CT-geführte Mikrowellenablation von Leber- und Lungentumoren durchführt.

Klinische Aktivitäten

Der Professor leitet das erste und einzige MRT-geführte FUS-Ablationszentrum im Rhein-Main-Gebiet. In den meisten Fällen vermeidet das Verfahren eine Operation. Ablation bei Prostatakrebs, Knochen- und Lebermetastasen, gutartigen Neubildungen, Behandlung von Uterusmyomen ohne chirurgischen Eingriff steht den Patienten des Zentrums zur Verfügung.

Mitgliedschaft in Organisationen

• DRG (Deutsche Gesellschaft für Radiologen).
• DeGIR (Deutsche Gesellschaft für Interventionelle Radiologie und Minimalinvasive Therapie).
• RSNA (Radiologische Gesellschaft von Nordamerika).
• ESGAR (Europäische Gesellschaft für Gastrointestinal- und Abdominalradiologie).
• CIRSE (Cardiovascular and Interventional Radiological Society of Europe).
• ECR (Europäischer Kongress für Radiologie).
• EUFUS (Europäische Gesellschaft für FUZ-Therapie).
• MEDICA (Deutsche Gesellschaft für Interdisziplinäre Medizin).

Professional Summary

Dr. Murat Balanlı is an experienced internal medicine specialist with over 35 years in the field of modern medicine. Since completing his medical education, Dr. Balanlı has continuously expanded his expertise, ultimately embracing a holistic approach to healthcare. Rather than seeing holistic medicine as an alternative, he regards it as an essential extension of conventional treatment that focuses on restoring the unity of mind, body, and spirit. His philosophy, rooted in the idea that medicine is a branch of philosophy, aims to treat not only physical symptoms but also the underlying disruptions to an individual’s overall sense of well-being.

Dr. Balanlı's commitment to lifelong learning, his respect for the arts, and his passion for exploring new perspectives on health have enriched his practice and deepened his connection with patients. His experience includes positions in hospital administration, health institution management, and public health, equipping him with a comprehensive understanding of the healthcare system and patient care at various levels.

*Educational Background

Doctor of Medicine (MD)
Ege University, Faculty of Medicine, 1988

Specialist Training in Internal Medicine
Tepecik Training and Research Hospital, 1994

Master’s Degree in Health Institutions Management
Başkent University, Faculty of Social Sciences, 2012

*Professional Experience

Healthy Living Clinic, Turkey

Founder and Head Practitioner
2014 - Present
Founded and oversees the Healthy Living Clinic, which offers personalized holistic treatment plans to patients. Here, Dr. Balanlı integrates modern medicine with holistic practices, aiming to support patients in achieving both physical health and emotional well-being.

SB Behçet Uz Children's Diseases and Surgery Training and Research Hospital

Hospital Administrator
2015 - 2018
Managed administrative and operational functions at one of Turkey's leading children's hospitals, ensuring high standards of healthcare delivery.

Social Security Institution (SGK), Izmir

Regional Director of Health Affairs
2004 - 2009
Oversaw healthcare services and managed regional health affairs for SGK, contributing to policy-making and service delivery improvements across the region.

Board Member
2009 - 2012
Served on the SGK Board of Directors, actively involved in shaping healthcare policies and advocating for quality, affordable healthcare.

Kayseri Ibn-i Sina Medical Centers

Chief Physician
2003 - 2008
Directed medical services, focusing on the integration of patient-centered care with evidence-based medical practices.

Tokat Niksar State Hospital

Chief Physician
1996
Completed mandatory service as a physician, gaining foundational experience in diverse clinical settings.

*Certifications and Advanced Training

• Neuroanatomy, Neuroelectrophysiology, and Biofeedback
  Completed in Romania
• Biorezonance Medicine and Applications
  Completed in Russia
  Specialized training in biorezonance therapy to support holistic approaches in addressing various chronic and stress-related conditions.

*Key Skills and Expertise

• Internal Medicine
• Holistic Medicine Approaches
• Holistic Wellness Approaches
•  
• Patient-Centered Care
• Biorezonance Therapy
• Health Systems Management
• Hospital and Healthcare Administration

Publications and Contributions

Dr. Balanlı has shared his insights on holistic medicine through articles, presentations, and community health talks, with a focus on bridging modern and holistic approaches. His dedication to sharing knowledge has made him a respected figure in both traditional and holistic medical communities.

Languages

• Turkish (Native)
• English (Fluent)
• Russian (Native)
• Azerbaijani (Fluent)

DR. Arzu Musaeva

Education: Azerbaijan Medical University.

Specialization: therapist

Working hours and days: weekdays 10:00-15:00.

Training and membership:

16.02-31.03.2000 thematic development of the cycle “Current issues of infectious diseases”.

02.01-15.02.2001 thematic cycle “Clinical pharmacotherapy of internal diseases”.

improvement.

01-30.12.2005 thematic improvement in the course “Chronic renal failure”.

22.11-27.12.2005 "Applied Homotoxicology" (56 hours) prof. Safihan Gasanov.

26-30.01.2006 "Applied Homotoxicology" (36 hours) Dr. Klaus Kuestermann (Baden-Baden,

Germany).

12-24.11.2006 "Applied Homotoxicology" (48 hours) Doctor of Technical Sciences Elena Nekrasova

23-28.04.2007 "Homeoisopathy" Dr. Burkhard Flechsig.

28.05-02.06.2007 "Sanum Therapy" Dr. Anita Krake (Germany).

13.12. 2008. “Microbiological Therapy” Doctor of Medical Sciences Michael Schreiber (Germany).

14-18.03.2008 "Module B" Dr. Marion Krasnitzer-Geyer, Dr. med. Siddhartha Popat (Baden-

Baden, Germany).

20-22.06.2008. "Acupuncture and Homeosiniatry" Dr. med. Siddhartha Popat (Baden-Baden,

Germany).

27-29.11.2009. "Introduction to Homeosiniatry" Dr. med. Joachim Bandlow.

02/16/2010. "Homotoxicology" Dr. Alta Smith.

05-09.11.2010. Course "Applied Homotoxicology" (36 hours). Dr. med. Burkhard Flechsig, Dr. med.

Joachim Bandlow.

21-22. 01.2011. "Introduction to Isopathy and Sanum Therapy". Med. Thomas Rau.

04.04.2011. "Microbiological Therapy" Dr. Kerstin Rasch, Dr. Volker Rusch.

10.20.2013. "Traditional medicine with biological medicine in diseases of the endocrinological and lymphatic systems"

"Sharing Methods" by Dr. Jurgen Frost.

07.04-02.05.2014 "Azerbaijan State Medical Institute named after A.Aliyev"

refresher course.

11/12/2014. "Inflammation: A New Concept" by Dr. Alta Smith.

10-11.04.2015. "Diabetes, Stress and Associated Diseases" Dr. med. Siddhartha Popat

(Baden-Baden, Germany).

12-16.05.2015. "Neurology, autoimmune diseases" Dr. of Medical Sciences Thomas Rau (Switzerland).

05/28/2015. "Basics of acid-base balance" "Hormones and health" Dr. med. Burkhard

Flechsig (Germany).

10.21.2015. "Fundamentals of Oncology" by Dr. Gerhard Reiss (Germany).

12/21/2015. "Mesotherapy" Dr. Alta Smith (Germany).

01-03.04.2016. Dr. "Allergy, Inflammation, Stress". Bert Hannosset (Germany).

05/28-29/2016 “Aesthetic Medicine” Dr. Tatiana Rivkina (Italy).

06/13-14/2016 “Fibromyalgia, Gout, Psoriasis” Dr. med. Gerhard Reis (Germany).

04-08.10.2016. "Mucosa Syndrome" Dr. Arturo Obirne (Colombia).

21.10. 2016. "Microbiological Therapy" by Dr. Uwe Peters (Germany).

31.10-01.11.2016. "Thyroid depletion syndrome" Dr. Gerhard Reiss (Germany).

10-11.11.2017. "Microbiological therapy – the basis of regulation" Dr. Uwe Peters (Germany).

12.2017. "Neurotherapy and Homotoxicology" Dr. med. Siddhartha Popat (Baden-Baden,

Germany).

2017. "Metabolic Syndrome" Dr. med. Annette Jaensch.

2017. "Healthy Aging, Proven Remedies in Integrative Medicine", Dr. Ralf Ottmaier

(Switzerland).

14-20.05.2018. "From segment to barrier, nutrition and inflammation, vitamin C and diabetes", doctor.

honey. Arturo Obirne (Colombia).

15-17.11.2018 "Elimination Therapy Methods, Success in Old Age" Dr. Marion Krasnitzer-Geyer

(Baden-Baden, Germany).

04.2018. "Bioregulatory treatment of chronic infections" Dr.rer.nat. Petra Grüning.

21-23.09.2018. "Possibilities of treating degenerative diseases using systemic bioregulatory medicine"

Doctor med. Siddhartha Popat (Baden-Baden, Germany).

01/25/2019. "Basics of mistletoe therapy with Helixor and its application in practice" Doctor of Medical Sciences Christfried

Preussler (Germany).

05/11/2019 “Mesotherapy” Dr. Nicoletta Frasca

05/14/2019. "Sanum Therapy for Liver Diseases" by Dr. Dieter Sonntag

06.04.2019. "Isn't fatigue the call of the liver?" Dr. Petra Grüning.

14-19.10.2019. "Bioregulatory treatment of dermatological diseases". med. Arturo Obirne

(Colombia).

Based on the results of successful treatment of trophic ulcers of various origins with biological preparations

Received the Hans-Heinrich Reckeweg Prize for clinical cases.

Examinations and treatment performed:

• Bioregulatory therapy of all therapeutic diseases.

• Atherosclerosis, stenosis, occlusion of peripheral arteries.

• Varicose veins, thrombophlebitis, thrombosis, lymphostasis of peripheral veins.

• Peripheral nerve neuropathy.

• Diabetic paw, osteoarthropathy, osteomyelitis.

• Detoxification and bioregulation of blood glucose at the cellular level. Diabetes mellitus

treatment and prevention of delayed complications in the lower extremities.

• Gangrenous pyoderma.

• Treatment of trophic ulcers.